Virtual Global Research and Trial Updates

Overview

Vania Broccoli presented on Wolfram syndrome, highlighting the role of the WFS1 gene and its protein, Wolframin, in protein synthesis and folding. She discussed the impact of WFS1 mutations on retinal ganglion cells, leading to optic atrophy and vision loss. Broccoli’s research involved gene replacement therapy using adeno-associated viral vectors to restore Wolframin function in both glial cells and retinal ganglion cells in mice. Preliminary results showed improved visual activity and reduced retinal ganglion cell loss in treated mice. The discussion also covered ongoing clinical trials with amalex and the challenges of obtaining GLP-1 agonists in the UK.

Action Items

• Introduce Vania to Jamie to discuss the patient group providing feedback on the ER stress inhibitor drug.
• Contact Alex to explore the possibility of a compassionate use program for the ER stress inhibitor drug in Europe.

Outline

Presentation Structure and Content

• Vania Broccoli explains the structure of her presentation, focusing on Wolfram syndrome and its impact on patients.
• Wolfram Syndrome UK mentions the importance of the presentation for planning future family conferences and international symposiums.
• Vania discusses the role of Wolfram protein in protein synthesis and folding, and its impact on cell stress and death.
• Wolfram Syndrome UK highlights the need for effective therapies and the challenges in obtaining certain medications in the UK.

Clinical Trials and Compassionate Use

• Stephanie Gebel updates on the phase three trial for amalex and the efforts to secure compassionate use for older patients.
• Stephanie mentions a 10-patient group for feedback on amalex, including international participants.
• Wolfram Syndrome UK discusses the challenges of obtaining GLP-1 agonists in the UK and the impact on patients.

Introduction of Dr. Vania Broccoli and Presentation Overview

• Wolfram Syndrome UK introduces Dr. Vania Broccoli and her presentation on new discoveries in Wolfram syndrome.
• Vania outlines her research focus on Wolfram syndrome and the importance of understanding the pathological basis of the disorder.
• She explains the multi-systemic nature of Wolfram syndrome and its impact on patients, particularly progressive vision loss.
• Vania describes the role of retina ganglion cells and the impact of Wolfram syndrome on the optic nerve and visual loss.

Mechanisms of Visual Loss in Wolfram Syndrome

• Vania details the mechanisms of visual loss in Wolfram syndrome, including the role of the WFS1 gene and its mutations.
• She explains the function of Wolfram protein in the endoplasmic reticulum and its role in protein synthesis and folding.
• Vania discusses the impact of Wolfram protein deficiency on endoplasmic reticulum stress and cell sufferance.
• She highlights the importance of understanding the multiple functions of Wolfram protein and its impact on different cellular processes.

Gene Replacement Therapy and Experimental Models

• Vania describes the use of Wolfram mutant mice as experimental models to study the disease and test therapeutic interventions.
• She explains the loss of retina ganglion cells in Wolfram mutant mice and the role of trophic glial cells in energy supply.
• She discusses the potential of gene replacement therapy to restore Wolfram protein function and improve cellular processes.
• Vania outlines the development of therapeutic viral vectors to express a functional copy of the WFS1 gene in glial cells and retina ganglion cells.

Therapeutic Efficacy and Future Directions

• Vania presents preliminary data on the efficacy of gene replacement therapy in Wolfram mutant mice.
• She highlights the importance of understanding which cell types should be targeted for gene replacement therapy.
• She discusses the potential for translating gene replacement therapy from mice to human patients.
• Vania emphasizes the need for further experimental evidence to support the development of gene replacement therapy for Wolfram syndrome.

Q&A Session and Closing Remarks

• Wolfram Syndrome UK asks about the involvement of Wolfram protein in protein transport and folding.
• Vania confirms that Wolfram protein is directly involved in protein folding and maturation.
• Wolfram Syndrome UK inquires about plans for gene replacement trials for Wolfram syndrome patients.
• Vania expresses confidence in the potential of gene replacement therapy and the need for further research to refine the approach.